See more : Site Group International Limited (SIT.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Huaren Pharmaceutical Co., Ltd. (300110.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Huaren Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Global Information, Inc. (4171.T) Income Statement Analysis – Financial Results
- Anything Technologies Media, Inc. (EXMT) Income Statement Analysis – Financial Results
- Aurcana Silver Corporation (AUNFF) Income Statement Analysis – Financial Results
- Hansa Investment Company Limited (HAN.L) Income Statement Analysis – Financial Results
- Topsports International Holdings Limited (6110.HK) Income Statement Analysis – Financial Results
Huaren Pharmaceutical Co., Ltd. (300110.SZ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.qdhuaren.com
About Huaren Pharmaceutical Co., Ltd.
Huaren Pharmaceutical Co., Ltd. produces and sells non-PVC soft bag infusions in China. The company offers doxofylline, levofloxacin hydrochloride, compound potassium hydrogen phosphate, and caffeine citrate, sodium chloride, glucose, glucose sodium potassium chloride, compound sodium chloride, sodium lactate ringer, compound electrolyte, and sterilized water injections. It also provides therapeutic infusion products for blood volume expansion, hemostasis, nervous and circulatory systems, anti-infection, anti-hepatitis, hepatitis adjuvant, anti-tumor, and carbohydrate metabolism; and medical instruments, such as disposable incision retractors, disposable cannula puncture devices disposable specimen extractors, abdominal suction tubes, incision retractor protectors, iodine solution protective caps, slip pads, respiratory oscillation expectoration machines, protective mask cup types, protective and foldable disposable masks, and medical protective masks. In addition, the company offers pharmaceutical packaging materials, including rubber stopper, carton, and membrane; rinsing fluid and API series products; and food and beverage, and medical skin care products. Huaren Pharmaceutical Co., Ltd. was founded in 1998 and is based in Qingdao, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.64B | 1.62B | 1.56B | 1.32B | 1.46B | 1.38B | 1.31B | 1.25B | 1.11B | 916.76M | 867.20M | 562.03M | 405.31M | 338.30M | 288.55M | 207.57M | 161.14M |
| Cost of Revenue | 937.20M | 918.71M | 771.35M | 752.34M | 634.03M | 586.50M | 610.78M | 689.31M | 609.57M | 475.06M | 406.30M | 246.41M | 177.25M | 146.87M | 123.92M | 97.55M | 87.65M |
| Gross Profit | 699.05M | 700.78M | 789.51M | 564.25M | 827.91M | 797.36M | 701.10M | 559.67M | 496.32M | 441.71M | 460.90M | 315.63M | 228.06M | 191.44M | 164.62M | 110.02M | 73.49M |
| Gross Profit Ratio | 42.72% | 43.27% | 50.58% | 42.86% | 56.63% | 57.62% | 53.44% | 44.81% | 44.88% | 48.18% | 53.15% | 56.16% | 56.27% | 56.59% | 57.05% | 53.00% | 45.60% |
| Research & Development | 68.68M | 55.30M | 63.68M | 55.22M | 62.43M | 56.02M | 48.58M | 52.80M | 53.50M | 46.19M | 40.88M | 20.12M | 12.82M | 7.00M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 17.31M | 18.90M | 22.76M | 17.69M | 26.54M | 29.34M | 29.81M | 32.89M | 25.50M | 15.78M | 18.45M | 13.53M | 6.24M | 5.53M | 3.09M | 926.55K | 1.09M |
| Selling & Marketing | 112.94M | 225.45M | 302.09M | 240.91M | 491.16M | 527.67M | 410.45M | 300.91M | 245.38M | 177.12M | 165.29M | 121.57M | 94.50M | 61.22M | 54.80M | 28.58M | 10.24M |
| SG&A | 262.24M | 244.35M | 324.85M | 258.60M | 517.70M | 557.01M | 440.26M | 333.80M | 270.88M | 192.89M | 183.74M | 135.10M | 100.74M | 66.75M | 57.89M | 29.51M | 11.33M |
| Other Expenses | 138.96M | 7.37M | -1.04M | -2.41M | -6.63M | -4.23M | -10.02M | -5.18M | 1.72M | -1.14M | 931.92K | 5.03M | 8.28M | 8.01M | 1.65M | 1.49M | 4.27M |
| Operating Expenses | 469.89M | 392.92M | 482.15M | 388.04M | 666.67M | 689.61M | 555.32M | 457.94M | 394.01M | 331.54M | 286.40M | 195.40M | 135.20M | 96.42M | 74.50M | 47.09M | 24.20M |
| Cost & Expenses | 1.41B | 1.31B | 1.25B | 1.14B | 1.30B | 1.28B | 1.17B | 1.15B | 1.00B | 806.60M | 692.69M | 441.81M | 312.46M | 243.29M | 198.42M | 144.64M | 111.86M |
| Interest Income | 2.16M | 4.77M | 1.80M | 4.75M | 5.21M | 6.87M | 610.35K | 736.64K | 1.30M | 1.12M | 1.51M | 2.83M | 8.06M | 2.99M | 687.88K | 170.72K | 82.53K |
| Interest Expense | 65.74M | 64.16M | 63.14M | 10.96M | 22.31M | 36.92M | 34.09M | 50.80M | 58.75M | 39.36M | 23.73M | 7.52M | 2.09M | 12.88M | 12.43M | 9.29M | 9.01M |
| Depreciation & Amortization | 135.40M | 160.61M | 151.39M | 130.39M | 144.34M | 144.37M | 154.86M | 149.55M | 114.71M | 97.50M | 85.64M | 42.38M | 32.52M | 31.08M | 19.31M | 12.83M | 12.15M |
| EBITDA | 431.65M | 419.61M | 348.34M | 236.04M | 206.11M | 196.83M | 261.19M | 236.60M | 197.77M | 200.64M | 252.72M | 160.02M | 138.78M | 123.53M | 96.01M | 77.40M | 53.21M |
| EBITDA Ratio | 26.38% | 28.54% | 27.89% | 22.11% | 18.88% | 16.15% | 18.48% | 16.90% | 19.66% | 22.74% | 30.32% | 30.51% | 34.90% | 40.50% | 38.50% | 37.46% | 40.72% |
| Operating Income | 225.94M | 198.49M | 151.30M | 114.04M | 74.04M | 47.79M | 63.82M | 32.24M | 22.66M | 65.07M | 142.82M | 112.64M | 95.24M | 84.07M | 74.79M | 54.29M | 36.76M |
| Operating Income Ratio | 13.81% | 12.26% | 9.69% | 8.66% | 5.06% | 3.45% | 4.87% | 2.58% | 2.05% | 7.10% | 16.47% | 20.04% | 23.50% | 24.85% | 25.92% | 26.16% | 22.82% |
| Total Other Income/Expenses | 4.57M | 7.37M | -1.04M | -2.41M | -6.63M | -4.23M | -10.02M | -5.20M | 1.66M | -1.28M | 528.22K | 5.00M | 8.28M | -1.73M | -10.77M | -7.30M | -4.82M |
| Income Before Tax | 230.51M | 205.86M | 150.26M | 111.64M | 67.41M | 43.56M | 53.80M | 27.03M | 24.31M | 63.79M | 143.35M | 117.64M | 103.52M | 92.08M | 76.43M | 55.78M | 41.04M |
| Income Before Tax Ratio | 14.09% | 12.71% | 9.63% | 8.48% | 4.61% | 3.15% | 4.10% | 2.16% | 2.20% | 6.96% | 16.53% | 20.93% | 25.54% | 27.22% | 26.49% | 26.87% | 25.47% |
| Income Tax Expense | 37.09M | 24.52M | 16.21M | 14.75M | 22.25M | 6.10M | 14.76M | 4.63M | 2.14M | 7.63M | 21.83M | 19.67M | 15.96M | 15.76M | 15.67M | 9.35M | 6.90M |
| Net Income | 188.06M | 180.78M | 130.40M | 94.62M | 42.07M | 38.79M | 37.54M | 23.95M | 22.94M | 56.15M | 121.52M | 96.59M | 87.56M | 76.32M | 60.77M | 46.43M | 34.14M |
| Net Income Ratio | 11.49% | 11.16% | 8.35% | 7.19% | 2.88% | 2.80% | 2.86% | 1.92% | 2.07% | 6.13% | 14.01% | 17.19% | 21.60% | 22.56% | 21.06% | 22.37% | 21.19% |
| EPS | 0.16 | 0.15 | 0.11 | 0.08 | 0.04 | 0.03 | 0.04 | 0.02 | 0.02 | 0.05 | 0.11 | 0.09 | 0.08 | 0.08 | 0.08 | 0.06 | 0.04 |
| EPS Diluted | 0.16 | 0.15 | 0.11 | 0.08 | 0.04 | 0.03 | 0.04 | 0.02 | 0.02 | 0.05 | 0.11 | 0.09 | 0.08 | 0.08 | 0.08 | 0.06 | 0.04 |
| Weighted Avg Shares Out | 1.18B | 1.18B | 1.18B | 1.18B | 1.18B | 1.15B | 985.17M | 1.21B | 1.15B | 1.21B | 1.10B | 1.13B | 1.10B | 917.10M | 784.97M | 773.92M | 767.00M |
| Weighted Avg Shares Out (Dil) | 1.18B | 1.18B | 1.18B | 1.18B | 1.18B | 1.15B | 985.17M | 1.21B | 1.15B | 1.21B | 1.10B | 1.13B | 1.10B | 917.10M | 784.97M | 773.92M | 767.00M |
Source: https://incomestatements.info
Category: Stock Reports